1st Quarter - Report

HEALTH INDUSTRY DISTRIBUTORS ASSOCIATION for HEALTH INDUSTRY DISTRIBUTORS ASSOCIATION

Firm
Client
Income
—
Expenses
$30,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Linda Rouse O'Neill ceased lobbying for HIDA on 2/7/2025 Medical Supply Chain Resiliency Act (S. 998/HR 2213) Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) either as standalone legislation or inclusion in a larger package such as S.891, the Bipartisan Health Care Act. Health cybersecurity legislation. Implementation of the Drug Supply Chain Security Act (DSCSA).

LobbyistCovered position, as disclosed
KATHRYN DIBITETTO —
CHRISTINA LAVOIE —
LINDA ROUSE-O'NEILL —
WYETH RUTHVEN —

Contacted: Federal Maritime Commission; Environmental Protection Agency (EPA); Federal Emergency Management Agency (FEMA); Commerce, Dept of (DOC); White House Office; Food & Drug Administration (FDA); Transportation, Dept of (DOT); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Bills named: S. 891 (119th), H.R. 2213 (119th), S. 998 (119th)

Transportation TRA

Linda Rouse O'Neill ceased lobbying for HIDA on 2/7/2025. S.257, the Promoting Resilient Supply Chains Act of 2025. Implementation of HR 6140, enacted as Section 3522 of Public Law 118-159:Facilitating Access to Swiftly Transport Goods during a Publicly Announced State of Emergency Situation (FAST PASS) Act. Monitoring of labor issues and work stoppages resulting from the International Longshoreman's Association strike affecting ports on the East Coast of the United States.

LobbyistCovered position, as disclosed
KATHRYN DIBITETTO —
CHRISTINA LAVOIE —
LINDA ROUSE-O'NEILL —
WYETH RUTHVEN —

Contacted: Federal Maritime Commission; SENATE; Health & Human Services, Dept of (HHS); Transportation, Dept of (DOT); White House Office; HOUSE OF REPRESENTATIVES

Bills named: S. 257 (119th), H.R. 6140 (119th)

Tariff (miscellaneous tariff bills) TAR

Linda Rouse O'Neill ceased lobbying for HIDA on 2/7/2025. Legislative and executive branch action with respect to tariffs and tariff exclusions on medical products: including IEEPA reciprocal tariffs, IEEPA border/fentanyl tariffs on China, Mexico and Canada, tariff investigations pursuant to Sec 301 and Sec 232 on medical products. Medical Supply Chain Resiliency Act (S. 998/HR 2213)

LobbyistCovered position, as disclosed
KATHRYN DIBITETTO —
CHRISTINA LAVOIE —
LINDA ROUSE-O'NEILL —
WYETH RUTHVEN —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; U.S. Trade Representative (USTR)

Bills named: S. 998 (119th), H.R. 2213 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.